学校法人順天堂　研究者情報データベース:::研究業績詳細:::

HOME　＞　研究業績詳細

研究業績詳細

窪田大介（クボタダイスケ）

研究テーマ	腫瘍学, 分子生物学, 骨軟部腫瘍, 骨転移
研究業績（論文）	Publication list: 1. Schoenfeld AJ, Chan JM, Kubota D, Sato H, Rizvi H, Daneshbod Y, Chang JC, Paik PK, Offin M, Arcila ME, Davare MA, Shinde U, Pe'er D, Rekhtman N, Kris MG, Somwar R, Riely GJ, Ladanyi M, Yu HA. Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <i>EGFR</i>-Mutant Lung Cancer. Clin Cancer Res. 2020 Jun 1;26(11):2654-2663 2. Vojnic M, Kubota D, Kurzatkowski C, Offin M, Suzawa K, Benayed R, Schoenfeld AJ, Plodkowski AJ, Poirier JT, Rudin CM, Kris MG, Rosen NX, Yu HA, Riely GJ, Arcila ME, Somwar R, Ladanyi M. Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. J Thorac Oncol. 2019 May;14(5):802-815. 3. Suehara Y, Akaike K, Mukaihara K, Kurisaki-Arakawa A, Kubota D, Okubo T, Mitomi H, Mitani K, Takahashi M, Toda-Ishii M, Kim Y, Tanabe Y, Takagi T, Hayashi T, Mogushi K, Kaneko K, Yao T, Saito T. KCTD12 is negatively regulated by Kit in gastrointestinal stromal tumors. Oncotarget. 2018 Jun 5;9(43):27016-27026. 4. Mukaihara K, Tanabe Y, Kubota D, Akaike K, Hayashi T, Mogushi K, Hosoya M, Sato S, Kobayashi E, Okubo T, Kim Y, Kohsaka S, Saito T, Kaneko K, Suehara Y. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma. PLoS One. 2017 Sep 25;12(9):e0185321 5. Kikuta K, Kubota D, Yoshida A, Qiao Z, Morioka H, Nakamura M, Matsumoto M, Chuman H, Kawai A, Kondo T. Discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2) is a novel biomarker of myxofibrosarcoma invasion identified by global protein expression profiling. Biochim Biophys Acta. 2017 Jun 29;1865(9):1160-1166. 6. Saito K, Kobayashi E, Yoshida A, Araki Y, Kubota D, Tanzawa Y, Kawai A, Yanagawa T, Takagishi K, Chuman H. Angiomatoid fibrous histiocytoma: a series of seven cases including genetically confirmed aggressive cases and a literature review. BMC Musculoskelet Disord. 2017 Jan 23;18(1):31. 7. Kubota D, Kosaka N, Fujiwara T, Yoshida A, Arai Y, Qiao Z, Takeshita F, Ochiya T, Kawai A, Kondo T. miR-125b and miR-100 Are Predictive Biomarkers of Response to Induction Chemotherapy in Osteosarcoma. Sarcoma. 2016;2016:1390571. 8. Toda-Ishii M, Akaike K, Suehara Y, Mukaihara K, Kubota D, Kohsaka S, Okubo T, Mitani K, Mogushi K, Takagi T, Kaneko K, Yao T, Saito T. Clinicopathological effects of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors. Mod Pathol. 2016 Nov;29(11):1424-1432. 9. Kim Y, Kobayashi E, Kubota D, Suehara Y, Mukaihara K, Akaike K, Ito A, Kaneko K, Chuman H, Kawai A, Kitano S. Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance. Oncotarget. 2016 Sep 23. doi: 10.18632/oncotarget.12225. 10. Mukaihara K, Suehara Y, Kohsaka S, Kubota D, Toda-Ishii M, Akaike K, Fujimura T, Kobayashi E, Yao T, Ladanyi M, Kaneko K, Saito T. Expression of F-actin-capping protein subunit beta, CAPZB, is associated with cell growth and motility in epithelioid sarcoma. BMC Cancer. 2016 Mar 10;16(1):206. 11. Mukaihara K, Suehara Y, Kohsaka S, Akaike K, Tanabe Y, Kubota D, Ishii M, Fujimura T, Kazuno S, Okubo T, Takagi T, Yao T, Kaneko K, Saito T. Protein Expression Profiling of Giant Cell Tumors of Bone Treated with Denosumab. PLoS One. 2016 Feb 10;11(2):e0148401. 12. Akaike K, Toda-Ishii M, Suehara Y, Mukaihara K, Kubota D, Mitani K, Takagi T, Kaneko K, Yao T, Saito T. TERT promoter mutations are a rare event in gastrointestinal stromal tumors. Springerplus. 2015 Dec 30;4:836. 13. Yamaga K, Kobayashi E, Kubota D, Setsu N, Tanaka Y, Minami Y, Tanzawa Y, Nakatani F, Kawai A, Chuman H. Pediatric myositis ossificans mimicking osteosarcoma. Pediatr Int. 2015 Oct;57(5):996-9. 14. Takagi T, Katagiri H, Kim Y, Suehara Y, Kubota D, Akaike K, Ishii M, Mukaihara K, Okubo T, Murata H, Takahashi M, Kaneko K, Saito T. Skeletal Metastasis of Unknown Primary Origin at the Initial Visit: A Retrospective Analysis of 286 Cases. PLoS One. 2015 Jun 26; 10(6):e0129428. 15. Orita H, Ito T, Kushida T, Sakurada M, Maekawa H, Wada R, Suehara Y, Kubota D, Sato K. Pfetin as a risk factor of recurrence in gastrointestinal stromal tumors. Biomed Res Int. 2014:651935. 2014 May 26. 16. Kikuta K, Kubota D, Yoshida A, Morioka H, Toyama Y, Chuuman H, Kawai A. An analysis of factors related to the tail-like pattern of myxofibrosarcoma seen on MRI. (Skeletal Radiol. 2014 Aug 30. ) 17. Mukaihara K, Kubota D, Yoshida A, Asano, Suehara Y, Kaneko K, Kawai A, Kondo T. Proteomic Profile of Epithelioid Sarcoma. J Proteomics Bioinform Vol.7.7 158-165 (2014) 　 18. Orita H, Ito T, Kushida T, Sakurada M, Maekawa H, Wada R, Suehara Y, Kubota D, Sato K. Pfetin as a risk factor of recurrence in gastrointestinal stromal tumors.(Biomed Res Int. 2014;2014:651935.) 19. Taoka M, Morofuji N, Yamauchi Y, Ojima H, Kubota D, Terukina G, Nobe Y, Nakayama H, Takahashi N, Kosuge T, Isobe T, Kondo T. Global PROTOMAP Profiling to Search for Biomarkers of Early-Recurrent Hepatocellular Carcinoma. J Proteome Res. 2014 Jul 7. 20. Fujiwara T, Katsuda T, Hagiwara K, Kosaka N, Yoshioka Y, Takahashi RU, Takeshita F, Kubota D, Kondo T, Ichikawa H, Yoshida A, Kobayashi E, Kawai A, Ozaki T, Ochiya T. Clinical relevance and therapeutic significance of　microRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells. Stem Cells. 2014 Apr;32(4):959-73. 21. Kubota D, Yoshida A, Kawai A, Kondo T. Proteomics identified overexpression of SET oncogene product and possible therapeutic utility of protein phosphatase 2A in alveolar soft part sarcoma. J Proteome Res. 2014 May 2;13(5):2250-61. 22. Kubota D, Yoshida A, Kikuta K, Saito T, Suehara Y, Gotoh M, Kawai A, Kondo T. Proteomic Approach to Gastrointestinal Stromal Tumor Identified Prognostic Biomarkers. Proteomics Bioinform Vol.7.1 010-016 (2014) 23. Kubota D, Yoshida A, Tsuda H, Suehara Y, Okubo T, Saito T, Orita H, Sato K, Taguchi T, Yao T, Kaneko K, Katai H, Kawai A, Kondo T. Gene expression network analysis of ETV1 reveals KCTD10 as a novel prognostic biomarker in gastrointestinal stromal tumor. PLoS One. 2013 Aug 19;8(8):e73896. 24. Kikuta K, Kubota D, Yoshida A, Suzuki Y, Morioka H, Toyama Y, Kobayashi E, Nakatani F, Chuuman H, Kawai A. An analysis of factors related to recurrence of myxofibrosarcoma. Jpn J Clin Oncol. 2013 Nov;43(11):1093-104. 25. Kubota D, Mukaihara K, Yoshida A, Tsuda H, Kawai A, Kondo T. Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma. J Proteomics. 2013 Oct 8;91:393-404. 26. Arai K, Sakamoto R, Kubota D, Kondo T. Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system. Proteomics. 2013 Aug;13(15):2351-60. 27. Suehara Y, Kubota D, Saito T. Tissue sample preparation for biomarker discovery. Methods Mol Biol. 2013;1002:13-23. 28. Kubota D, Mukaihara K, Yoshida A, Suehara Y, Saito T, Okubo T, Gotoh M, Orita H, Tsuda H, Sato K, Yao T, Kaneko K, Kawai A, Kondo T. The prognostic value of pfetin: a validation study in gastrointestinal stromal tumors using a commercially available antibody. Jpn J Clin Oncol. 2013 Jun;43(6):669-75. 29. Haga A, Ogawara Y, Kubota D, Kitabayashi I, Murakami Y, Kondo T. Interactomic approach for evaluating nucleophosmin-binding proteins as biomarkers for Ewing's sarcoma. Electrophoresis. 2013 Jun;34(11):1670-8. 30. Kondo T, Suehara Y, Kikuta K, Kubota D, Tajima T, Mukaihara K, Ichikawa H, Kawai A. Proteomic approach toward personalized sarcoma treatment: lessons from prognostic biomarker discovery in gastrointestinal stromal tumor. Proteomics Clin Appl. 2013 Jan;7(1-2):70-8. 31. Suehara Y, Kubota D, Kikuta K, Kaneko K, Kawai A, Kondo T. Discovery of biomarkers for osteosarcoma by proteomics approaches. Sarcoma. 2012;2012:425636. 32. Sugihara Y, Taniguchi H, Kushima R, Tsuda H, Kubota D, Ichikawa H, Fujita S, Kondo T. Laser microdissection and two-dimensional difference gel electrophoresis reveal proteomic intra-tumor heterogeneity in colorectal cancer. J Proteomics. 2013 Jan 14;78:134-47. 33. Kimura K, Ojima H, Kubota D, Sakumoto M, Nakamura Y, Tomonaga T, Kosuge T, Kondo T. Proteomic identification of the macrophage-capping protein as a protein contributing to the malignant features of hepatocellular carcinoma. J Proteomics. 2013 Jan 14;78:362-73. 34. Kondo T, Kubota D, Kawai A. Application of proteomics to soft tissue sarcomas. Int J Proteomics. 2012;2012:876401. 35. Sugihara Y, Taniguchi H, Kushima R, Tsuda H, Kubota D, Ichikawa H, Sakamoto K, Nakamura Y, Tomonaga T, Fujita S, Kondo T. Proteomic-based identification of the APC-binding protein EB1 as a candidate of novel tissue biomarker and therapeutic target for colorectal cancer. J Proteomics. 2012 Sep 18;75(17):5342-55. 36. Kubota D, Okubo T, Saito T, Suehara Y, Yoshida A, Kikuta K, Tsuda H, Katai H, Shimada Y, Kaneko K, Kawai A, Kondo T. Validation study on pfetin and ATP-dependent RNA helicase DDX39 as prognostic biomarkers in gastrointestinal stromal tumour. Jpn J Clin Oncol. 2012 Aug;42(8):730-41. 37. Kikuta K, Kubota D, Saito T, Orita H, Yoshida A, Tsuda H, Suehara Y, Katai H, Shimada Y, Toyama Y, Sato K, Yao T, Kaneko K, Beppu Y, Murakami Y, Kawai A, Kondo T. Clinical proteomics identified ATP-dependent RNA helicase DDX39 as a novel biomarker to predict poor prognosis of patients with gastrointestinal stromal tumor. J Proteomics. 2012 Feb 2;75(4):1089-98. 38. Kubota D, Orita H, Yoshida A, Gotoh M, Kanda T, Tsuda H, Hasegawa T, Katai H, Shimada Y, Kaneko K, Kawai A, Kondo T. Pfetin as a prognostic biomarker forgastrointestinal stromal tumor: validation study in multiple clinical facilities. Jpn J Clin Oncol. 2011 Oct;41(10):1194-202. 39. Suehara Y, Tochigi N, Kubota D, Kikuta K, Nakayama R, Seki K, Yoshida A, Ichikawa H, Hasegawa T, Kaneko K, Chuman H, Beppu Y, Kawai A, Kondo T. Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics. J Proteomics. 2011 May 16;74(6):829-42. Grant 2020- 　　Japan Society for the Promotion of Science (JSPS): 　　Grant-in-Aid for Scientific Research (C). 2016-2019　　　Japan Society for the Promotion of Science (JSPS): 　　　Fund for the Promotion of Joint International Research (Fostering Joint International Research) 2015 　　Takeda science foundation: Grant-in-Aid for Medical Science 2015-2016 Japan Society for the Promotion of Science (JSPS): Grants-in-Aid for Young Scientists (B) 2015-　Grant of Japan Orthopaedics and Traumatology Research Foundation 2013-2016 Japan Society for the Promotion of Science (JSPS): Grants-in-Aid for Young Scientists (B)

研究テーマ

腫瘍学, 分子生物学, 骨軟部腫瘍, 骨転移

研究業績（論文）

Publication list:
1. Schoenfeld AJ, Chan JM, Kubota D, Sato H, Rizvi H, Daneshbod Y, Chang JC, Paik PK, Offin M, Arcila ME, Davare MA, Shinde U, Pe'er D, Rekhtman N, Kris MG, Somwar R, Riely GJ, Ladanyi M, Yu HA. Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <i>EGFR</i>-Mutant Lung Cancer. Clin Cancer Res. 2020 Jun 1;26(11):2654-2663
2. Vojnic M, Kubota D, Kurzatkowski C, Offin M, Suzawa K, Benayed R, Schoenfeld AJ, Plodkowski AJ, Poirier JT, Rudin CM, Kris MG, Rosen NX, Yu HA, Riely GJ, Arcila ME, Somwar R, Ladanyi M. Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. J Thorac Oncol. 2019 May;14(5):802-815.
3. Suehara Y, Akaike K, Mukaihara K, Kurisaki-Arakawa A, Kubota D, Okubo T, Mitomi H, Mitani K, Takahashi M, Toda-Ishii M, Kim Y, Tanabe Y, Takagi T, Hayashi T, Mogushi K, Kaneko K, Yao T, Saito T. KCTD12 is negatively regulated by Kit in gastrointestinal stromal tumors. Oncotarget. 2018 Jun 5;9(43):27016-27026.
4. Mukaihara K, Tanabe Y, Kubota D, Akaike K, Hayashi T, Mogushi K, Hosoya M, Sato S, Kobayashi E, Okubo T, Kim Y, Kohsaka S, Saito T, Kaneko K, Suehara Y. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma. PLoS One. 2017 Sep 25;12(9):e0185321
5. Kikuta K, Kubota D, Yoshida A, Qiao Z, Morioka H, Nakamura M, Matsumoto M, Chuman H, Kawai A, Kondo T. Discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2) is a novel biomarker of myxofibrosarcoma invasion identified by global
protein expression profiling. Biochim Biophys Acta. 2017 Jun 29;1865(9):1160-1166.
6. Saito K, Kobayashi E, Yoshida A, Araki Y, Kubota D, Tanzawa Y, Kawai A, Yanagawa T, Takagishi K, Chuman H. Angiomatoid fibrous histiocytoma: a series of seven cases including genetically confirmed aggressive cases and a literature review. BMC Musculoskelet Disord. 2017 Jan 23;18(1):31.
7. Kubota D, Kosaka N, Fujiwara T, Yoshida A, Arai Y, Qiao Z, Takeshita F, Ochiya T, Kawai A, Kondo T. miR-125b and miR-100 Are Predictive Biomarkers of Response to Induction Chemotherapy in Osteosarcoma. Sarcoma. 2016;2016:1390571.
8. Toda-Ishii M, Akaike K, Suehara Y, Mukaihara K, Kubota D, Kohsaka S, Okubo T, Mitani K, Mogushi K, Takagi T, Kaneko K, Yao T, Saito T. Clinicopathological effects of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors. Mod Pathol. 2016 Nov;29(11):1424-1432.
9. Kim Y, Kobayashi E, Kubota D, Suehara Y, Mukaihara K, Akaike K, Ito A, Kaneko K, Chuman H, Kawai A, Kitano S. Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance. Oncotarget. 2016 Sep 23. doi: 10.18632/oncotarget.12225.
10. Mukaihara K, Suehara Y, Kohsaka S, Kubota D, Toda-Ishii M, Akaike K, Fujimura T, Kobayashi E, Yao T, Ladanyi M, Kaneko K, Saito T. Expression of F-actin-capping protein subunit beta, CAPZB, is associated with cell growth and motility in epithelioid sarcoma. BMC Cancer. 2016 Mar 10;16(1):206.
11. Mukaihara K, Suehara Y, Kohsaka S, Akaike K, Tanabe Y, Kubota D, Ishii M, Fujimura T, Kazuno S, Okubo T, Takagi T, Yao T, Kaneko K, Saito T. Protein Expression Profiling of Giant Cell Tumors of Bone Treated with Denosumab. PLoS One. 2016 Feb 10;11(2):e0148401.
12. Akaike K, Toda-Ishii M, Suehara Y, Mukaihara K, Kubota D, Mitani K, Takagi T, Kaneko K, Yao T, Saito T. TERT promoter mutations are a rare event in gastrointestinal stromal tumors. Springerplus. 2015 Dec 30;4:836.
13. Yamaga K, Kobayashi E, Kubota D, Setsu N, Tanaka Y, Minami Y, Tanzawa Y, Nakatani F, Kawai A, Chuman H. Pediatric myositis ossificans mimicking osteosarcoma. Pediatr Int. 2015 Oct;57(5):996-9.
14. Takagi T, Katagiri H, Kim Y, Suehara Y, Kubota D, Akaike K, Ishii M, Mukaihara K, Okubo T, Murata H, Takahashi M, Kaneko K, Saito T. Skeletal Metastasis of Unknown Primary Origin at the Initial Visit: A Retrospective Analysis of 286 Cases. PLoS One. 2015 Jun 26; 10(6):e0129428.
15. Orita H, Ito T, Kushida T, Sakurada M, Maekawa H, Wada R, Suehara Y, Kubota D, Sato K. Pfetin as a risk factor of recurrence in gastrointestinal stromal tumors. Biomed Res Int. 2014:651935. 2014 May 26.
16. Kikuta K, Kubota D, Yoshida A, Morioka H, Toyama Y, Chuuman H, Kawai A. An analysis of factors related to the tail-like pattern of myxofibrosarcoma seen on MRI. (Skeletal Radiol. 2014 Aug 30. )
17. Mukaihara K, Kubota D, Yoshida A, Asano, Suehara Y, Kaneko K, Kawai A, Kondo T. Proteomic Profile of Epithelioid Sarcoma. J Proteomics Bioinform Vol.7.7 158-165 (2014) 　
18. Orita H, Ito T, Kushida T, Sakurada M, Maekawa H, Wada R, Suehara Y, Kubota D, Sato K. Pfetin as a risk factor of recurrence in gastrointestinal stromal tumors.(Biomed Res Int. 2014;2014:651935.)
19. Taoka M, Morofuji N, Yamauchi Y, Ojima H, Kubota D, Terukina G, Nobe Y, Nakayama H, Takahashi N, Kosuge T, Isobe T, Kondo T. Global PROTOMAP Profiling to Search for Biomarkers of Early-Recurrent Hepatocellular Carcinoma. J Proteome Res. 2014 Jul 7.
20. Fujiwara T, Katsuda T, Hagiwara K, Kosaka N, Yoshioka Y, Takahashi RU, Takeshita F, Kubota D, Kondo T, Ichikawa H, Yoshida A, Kobayashi E, Kawai A, Ozaki T, Ochiya T. Clinical relevance and therapeutic significance of　microRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells. Stem Cells. 2014 Apr;32(4):959-73.
21. Kubota D, Yoshida A, Kawai A, Kondo T. Proteomics identified overexpression of SET oncogene product and possible therapeutic utility of protein phosphatase 2A in alveolar soft part sarcoma. J Proteome Res. 2014 May 2;13(5):2250-61.
22. Kubota D, Yoshida A, Kikuta K, Saito T, Suehara Y, Gotoh M, Kawai A, Kondo T. Proteomic Approach to Gastrointestinal Stromal Tumor Identified Prognostic Biomarkers. Proteomics Bioinform Vol.7.1 010-016 (2014)
23. Kubota D, Yoshida A, Tsuda H, Suehara Y, Okubo T, Saito T, Orita H, Sato K, Taguchi T, Yao T, Kaneko K, Katai H, Kawai A, Kondo T. Gene expression network analysis of ETV1 reveals KCTD10 as a novel prognostic biomarker in gastrointestinal stromal tumor. PLoS One. 2013 Aug 19;8(8):e73896.
24. Kikuta K, Kubota D, Yoshida A, Suzuki Y, Morioka H, Toyama Y, Kobayashi E, Nakatani F, Chuuman H, Kawai A. An analysis of factors related to recurrence of myxofibrosarcoma. Jpn J Clin Oncol. 2013 Nov;43(11):1093-104.
25. Kubota D, Mukaihara K, Yoshida A, Tsuda H, Kawai A, Kondo T. Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma. J Proteomics. 2013 Oct 8;91:393-404.
26. Arai K, Sakamoto R, Kubota D, Kondo T. Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system. Proteomics. 2013 Aug;13(15):2351-60.
27. Suehara Y, Kubota D, Saito T. Tissue sample preparation for biomarker discovery. Methods Mol Biol. 2013;1002:13-23.
28. Kubota D, Mukaihara K, Yoshida A, Suehara Y, Saito T, Okubo T, Gotoh M, Orita H, Tsuda H, Sato K, Yao T, Kaneko K, Kawai A, Kondo T. The prognostic value of pfetin: a validation study in gastrointestinal stromal tumors using a commercially available antibody. Jpn J Clin Oncol. 2013 Jun;43(6):669-75.
29. Haga A, Ogawara Y, Kubota D, Kitabayashi I, Murakami Y, Kondo T. Interactomic approach for evaluating nucleophosmin-binding proteins as biomarkers for Ewing's sarcoma. Electrophoresis. 2013 Jun;34(11):1670-8.
30. Kondo T, Suehara Y, Kikuta K, Kubota D, Tajima T, Mukaihara K, Ichikawa H, Kawai A. Proteomic approach toward personalized sarcoma treatment: lessons from prognostic biomarker discovery in gastrointestinal stromal tumor. Proteomics Clin Appl. 2013 Jan;7(1-2):70-8.
31. Suehara Y, Kubota D, Kikuta K, Kaneko K, Kawai A, Kondo T. Discovery of biomarkers for osteosarcoma by proteomics approaches. Sarcoma. 2012;2012:425636.
32. Sugihara Y, Taniguchi H, Kushima R, Tsuda H, Kubota D, Ichikawa H, Fujita S, Kondo T. Laser microdissection and two-dimensional difference gel electrophoresis reveal proteomic intra-tumor heterogeneity in colorectal cancer. J Proteomics. 2013 Jan 14;78:134-47.
33. Kimura K, Ojima H, Kubota D, Sakumoto M, Nakamura Y, Tomonaga T, Kosuge T, Kondo T. Proteomic identification of the macrophage-capping protein as a protein contributing to the malignant features of hepatocellular carcinoma. J Proteomics. 2013 Jan 14;78:362-73.
34. Kondo T, Kubota D, Kawai A. Application of proteomics to soft tissue sarcomas. Int J Proteomics. 2012;2012:876401.
35. Sugihara Y, Taniguchi H, Kushima R, Tsuda H, Kubota D, Ichikawa H, Sakamoto K, Nakamura Y, Tomonaga T, Fujita S, Kondo T. Proteomic-based identification of the APC-binding protein EB1 as a candidate of novel tissue biomarker and therapeutic target for colorectal cancer. J Proteomics. 2012 Sep 18;75(17):5342-55.
36. Kubota D, Okubo T, Saito T, Suehara Y, Yoshida A, Kikuta K, Tsuda H, Katai H, Shimada Y, Kaneko K, Kawai A, Kondo T. Validation study on pfetin and ATP-dependent RNA helicase DDX39 as prognostic biomarkers in gastrointestinal stromal tumour. Jpn J Clin Oncol. 2012 Aug;42(8):730-41.
37. Kikuta K, Kubota D, Saito T, Orita H, Yoshida A, Tsuda H, Suehara Y, Katai H, Shimada Y, Toyama Y, Sato K, Yao T, Kaneko K, Beppu Y, Murakami Y, Kawai A, Kondo T. Clinical proteomics identified ATP-dependent RNA helicase DDX39 as a novel biomarker to predict poor prognosis of patients with gastrointestinal stromal tumor. J Proteomics. 2012 Feb 2;75(4):1089-98.
38. Kubota D, Orita H, Yoshida A, Gotoh M, Kanda T, Tsuda H, Hasegawa T, Katai H, Shimada Y, Kaneko K, Kawai A, Kondo T. Pfetin as a prognostic biomarker forgastrointestinal stromal tumor: validation study in multiple clinical facilities. Jpn J Clin Oncol. 2011 Oct;41(10):1194-202.
39. Suehara Y, Tochigi N, Kubota D, Kikuta K, Nakayama R, Seki K, Yoshida A, Ichikawa H, Hasegawa T, Kaneko K, Chuman H, Beppu Y, Kawai A, Kondo T. Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics. J Proteomics. 2011 May 16;74(6):829-42.

Grant
2020-
　　Japan Society for the Promotion of Science (JSPS):
　　Grant-in-Aid for Scientific Research (C).
2016-2019　
　　Japan Society for the Promotion of Science (JSPS):
　　　Fund for the Promotion of Joint International Research (Fostering Joint International Research)
2015
　　Takeda science foundation:
Grant-in-Aid for Medical Science
2015-2016
Japan Society for the Promotion of Science (JSPS):
Grants-in-Aid for Young Scientists (B)

2015-　Grant of Japan Orthopaedics and Traumatology Research Foundation

2013-2016
Japan Society for the Promotion of Science (JSPS):
Grants-in-Aid for Young Scientists (B)

研究者

教育活動

【学校法人順天堂】研究者情報データベース

研究業績詳細

窪田 大介（クボタ ダイスケ）

窪田大介（クボタダイスケ）